Treatment approaches and biomarkers PRevalence In de novo MEtastatic hormone-sensitive prostate cancer in Russian Federation

Trial Identifier: D133HR00058
Sponsor: AstraZeneca
Start Date: June 2025
Primary Completion Date: June 2027
Study Completion Date: June 2027
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Barnaul, Russia
Russia Chelyabinsk, Russia
Russia Ekaterinburg, Russia
Russia Irkutsk, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Moscow, Russia
Russia Nizhny Novgorod, Russia
Russia Obninsk, Russia
Russia Omsk, Russia
Russia Saint Petersburg, Russia
Russia Saransk, Russia
Russia Tomsk, Russia
Russia Tyumen, Russia
Russia Ufa, Russia